{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:17:32Z","timestamp":1791839852893,"version":"4.3.4"},"reference-count":174,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Cutaneous manifestations of hematologic malignancy represent both a clinical challenge for the treating physician and a pathophysiological model for advancing the knowledge on individual neoplasms. Indeed, a growing body of evidence supports the concept of recurrent molecular defects associating with specific clinical features, as best exemplified by VEXAS. Herein neutrophilic and eosinophilic dermatoses of potential interest for both hematologists and dermatologists will be reviewed, including subcorneal pustular dermatosis-type IgA pemphigus, neutrophilic eccrine hidradenitis, Sweet\u2019s syndrome as well as myelodysplasia cutis and VEXAS, pyoderma gangrenosum, eosinophilic annular erythema, eosinophilic dermatosis of hematological malignancy, Wells syndrome and cutaneous involvement in hypereosinophilic syndromes. Possible management approaches are discussed for each, emphasizing scenarios that require treatment of the underlying condition to achieve remission at the skin level.<\/jats:p>","DOI":"10.3389\/fmed.2023.1324258","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T05:22:02Z","timestamp":1704432122000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Neutrophilic and eosinophilic dermatoses associated with hematological malignancy"],"prefix":"10.3389","volume":"10","author":[{"given":"Carlo Alberto","family":"Maronese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Derlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Moltrasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jid.2019.06.153","article-title":"Somatic mosaic NLRP3 mutations and Inflammasome activation in late-onset chronic Urticaria","volume":"140","author":"Assrawi","year":"2020","journal-title":"J Invest Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1056\/NEJMc2212928","article-title":"TET2-driver and NLRC4-passenger variants in adult-onset autoinflammation","volume":"388","author":"De Langhe","year":"2023","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40257-020-00553-9","article-title":"Immune-mediated dermatoses in patients with Haematological malignancies: a comprehensive review","volume":"21","author":"Maglie","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12016-017-8621-8","article-title":"A comprehensive review of neutrophilic diseases","volume":"54","author":"Marzano","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40257-020-00520-4","article-title":"Eosinophilic dermatoses: recognition and management","volume":"21","author":"Marzano","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"ref7","unstructured":"2009"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/archdermatol.2009.224","article-title":"Subcorneal pustular dermatosis-type IgA pemphigus with autoantibodies to desmocollins 1, 2, and 3","volume":"145","author":"D\u00fcker","year":"2009","journal-title":"Arch Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/B978-0-7020-6896-6.00063-6","article-title":"Bullous diseases of the skin and mucous membranes","volume":"2019","author":"Cardones","year":"2019","journal-title":"Clin. Immunol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.jaad.2019.11.059","article-title":"IgA pemphigus: a systematic review","volume":"82","author":"Kridin","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref11","first-page":"890","article-title":"Dermatose neutrophilique \u00e0 IgA intra-\u00e9pidermique associ\u00e9e \u00e0 un my\u00e9lome \u00e0 IgA [Intra-epidermal neutrophilic IgA dermatosis associated with IgA myeloma]","volume":"117","author":"Bernard","year":"1990","journal-title":"Ann Dermatol Venereol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000246947","article-title":"Subcorneal pustular dermatosis associated with IgA myeloma and intraepidermal IgA deposits","author":"Takata","year":"1994","journal-title":"Dermatology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.clml.2011.06.014","article-title":"Multiple myeloma associated IgA pemphigus: treatment with bortezomib- and lenalidomide-based regimen","volume":"11","author":"Szturz","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1111\/ijd.13721","article-title":"IgA multiple myeloma in a patient with an IgG pemphigus foliaceus-like exanthem","volume":"56","author":"Lee","year":"2017","journal-title":"Int J Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/1346-8138.16516","article-title":"Subcorneal pustular dermatosis-type IgA pemphigus associated with multiple myeloma: a case report and literature review","volume":"50","author":"Koga","year":"2023","journal-title":"J Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/s0190-9622(98)70093-3","article-title":"Subcorneal pustular dermatosis in a patient with aplastic anemia","volume":"39","author":"Park","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5070\/D336N564F4","article-title":"Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) occurring in association with nodal marginal zone lymphoma: a case report","volume":"14","author":"Ratnarathorn","year":"2008","journal-title":"Dermatol Online J"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1080\/00015550310016661","article-title":"Subcorneal pustular dermatosis in association with chronic lymphocytic leukaemia","volume":"83","author":"Brown","year":"2003","journal-title":"Acta Derm Venereol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/jdv.18931","article-title":"S2k guidelines on the management of paraneoplastic pemphigus\/paraneoplastic autoimmune multiorgan syndrome initiated by the European academy of dermatology and venereology (EADV)","volume":"37","author":"Antiga","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1365-2230.2008.02706.x","article-title":"Subcorneal pustular dermatosis: 50 years on","volume":"33","author":"Cheng","year":"2008","journal-title":"Clin Exp Dermatol"},{"key":"ref21","article-title":"Neutrophilic eccrine hidradenitis","volume-title":"StatPearls","author":"Crane","year":"2023"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.abd.2022.08.005","article-title":"Dermatological manifestations of hematologic neoplasms. Part II: nonspecific skin lesions\/paraneoplastic diseases","volume":"98","author":"de Souza","year":"2023","journal-title":"An Bras Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/archderm.1993.01680270135026","article-title":"Neutrophilic eccrine hidradenitis heralding the onset of acute myelogenous leukemia","volume":"129","author":"Pierson","year":"1993","journal-title":"Arch Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.blre.2017.07.003","article-title":"The skin as a window to the blood: cutaneous manifestations of myeloid malignancies","volume":"31","author":"Li","year":"2017","journal-title":"Blood Rev"},{"key":"ref25","first-page":"420","article-title":"Hidrad\u00e9nite eccrine neutrophilique associ\u00e9e \u00e0 une rechute de leuc\u00e9mie aigu\u00eb my\u00e9loblastique [Neutrophilic eccrine hidradenitis associated with relapse of acute myeloblastic leukemia]","volume":"125","author":"Saada","year":"1998","journal-title":"Ann Dermatol Venereol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/s0755-4982(06)74837-0","article-title":"Hidrad\u00e9nite eccrine neutrophilique idiopathique de l\u2019adulte d\u2019\u00e9volution prolong\u00e9e trait\u00e9e par colchicine [Adult idiopathic neutrophilic eccrine hidradenitis treated with colchicine]","volume":"35","author":"Belot","year":"2006","journal-title":"Presse Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1365-4632.2006.02605.x","article-title":"Neutrophilic dermatoses occurring in oncology patients","volume":"46","author":"Cohen","year":"2007","journal-title":"Int J Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1159\/000356229","article-title":"A classic clinical case: neutrophilic eccrine hidradenitis","volume":"5","author":"Copaescu","year":"2013","journal-title":"Case Rep Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40257-022-00673-4","article-title":"New practical aspects of sweet syndrome","volume":"23","author":"Joshi","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1159\/000530519","article-title":"Sweet syndrome: a review of published Cases","volume":"239","author":"Orfaly","year":"2023","journal-title":"Dermatology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00277-022-04850-7","article-title":"Characteristics of sweet syndrome in patients with or without malignancy","volume":"101","author":"Jung","year":"2022","journal-title":"Ann Hematol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fmed.2020.00020","article-title":"Insights into the characteristics of sweet syndrome in patients with and without hematologic malignancy","volume":"7","author":"Zheng","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jaad.2017.09.013","article-title":"Sweet syndrome in patients with and without malignancy: a retrospective analysis of 83 patients from a tertiary academic referral center","volume":"78","author":"Nelson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1001\/jamadermatol.2016.6092","article-title":"Clinicopathologic, Immunohistochemical, and molecular features of Histiocytoid sweet syndrome","volume":"153","author":"Alegr\u00eda-Landa","year":"2017","journal-title":"JAMA Dermatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.jaad.2020.02.048","article-title":"Risk of malignancy in histiocytoid sweet syndrome: a systematic review and reappraisal","volume":"83","author":"Haber","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref36","first-page":"167","article-title":"Diagnostic criteria for Sweet\u2019s syndrome","volume":"37","author":"Su","year":"1986","journal-title":"Cutis"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/s0190-9622(94)70215-2","article-title":"Sweet\u2019s syndrome (acute febrile neutrophilic dermatosis)","volume":"31","author":"von den Driesch","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/s0190-9622(96)90080-8","article-title":"Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet\u2019s syndrome","volume":"34","author":"Walker","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/ddg.13350","article-title":"Sweet\u2019s syndrome: diagnostic criteria revisited","volume":"15","author":"Nofal","year":"2017","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"adv00647","DOI":"10.2340\/actadv.v102.1123","article-title":"Leukaemia cutis: clinical features and outcomes of 56 patients","volume":"102","author":"Yook","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1182\/blood.2021014788","article-title":"Skin in the game: the emergence of myelodysplasia cutis","volume":"139","author":"Calvo","year":"2022","journal-title":"Blood"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1182\/blood.2021013967","article-title":"Clinical, pathological, and molecular features of myelodysplasia cutis","volume":"139","author":"Delaleu","year":"2022","journal-title":"Blood"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.jaad.2022.01.042","article-title":"VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) for the dermatologist","volume":"89","author":"Sterling","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1111\/j.1365-4632.2011.05141.x","article-title":"Distinct variant of Sweet\u2019s syndrome: bortezomib-induced histiocytoid Sweet\u2019s syndrome in a patient with multiple myeloma","volume":"51","author":"Kim","year":"2012","journal-title":"Int J Dermatol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.jaad.2022.10.052","article-title":"Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: a multicenter retrospective study of 59 cases","volume":"88","author":"Zakine","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"e775","DOI":"10.1097\/HS9.0000000000000775","article-title":"UBA1 screening in sweet syndrome with hematological neoplasms reveals a novel association between VEXAS and chronic Myelomonocytic leukemia","volume":"6","author":"Gurnari","year":"2022","journal-title":"Hema"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"106461","DOI":"10.1016\/j.leukres.2020.106461","article-title":"Sweet\u2019s syndrome associated with hematological malignancies","volume":"99","author":"Maller","year":"2020","journal-title":"Leuk Res"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood.2022016642","article-title":"Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study","volume":"140","author":"Heiblig","year":"2022","journal-title":"Blood"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1093\/rheumatology\/kead240","article-title":"How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies","volume":"62","author":"Boyadzhieva","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1053\/j.seminhematol.2021.10.007","article-title":"Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome","volume":"58","author":"Patel","year":"2021","journal-title":"Semin Hematol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1111\/jdv.12566","article-title":"Erythema elevatum diutinum: a review of presentation and treatment","volume":"28","author":"Momen","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/ijd.14169","article-title":"Erythema elevatum diutinum: a case report and review of literature","volume":"58","author":"Doktor","year":"2019","journal-title":"Int J Dermatol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.clindermatol.2019.07.028","article-title":"Erythema elevatum et diutinum as a systemic disease","volume":"37","author":"Sandhu","year":"2019","journal-title":"Clin Dermatol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.htct.2017.11.005","article-title":"Pyoderma gangrenosum and erythema elevatum diutinum associated with a high-risk myelodysplastic syndrome: case report","volume":"40","author":"Vide","year":"2018","journal-title":"Hematol Transfus Cell Ther"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40257-022-00699-8","article-title":"Pyoderma Gangrenosum: an updated literature review on established and emerging pharmacological treatments","volume":"23","author":"Maronese","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41572-020-0213-x","article-title":"Pyoderma gangrenosum","volume":"6","author":"Maverakis","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/j.1365-4632.2004.02128.x","article-title":"Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria","volume":"43","author":"Su","year":"2004","journal-title":"Int J Dermatol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamadermatol.2017.5980","article-title":"Diagnostic criteria of ulcerative pyoderma Gangrenosum: a Delphi consensus of international experts","volume":"154","author":"Maverakis","year":"2018","journal-title":"JAMA Dermatol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bjd.16401","article-title":"The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum","volume":"180","author":"Jockenh\u00f6fer","year":"2019","journal-title":"Br J Dermatol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jid.2020.04.019","article-title":"Comparison of three diagnostic frameworks for pyoderma Gangrenosum","volume":"141","author":"Haag","year":"2021","journal-title":"J Invest Dermatol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00403-022-02424-1","article-title":"The \u201cunderstanding pyoderma Gangrenosum, review and assessment of disease effects (UPGRADE)\u201d project: a protocol for the development of the core outcome domain set for trials in pyoderma gangrenosum","volume":"315","author":"Rick","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/ajd.13840","article-title":"Pyoderma gangrenosum: a review of patient\u2019s demographics, disease and treatment in 118 patients","volume":"63","author":"Honigman","year":"2022","journal-title":"Australas J Dermatol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jamadermatol.2017.5978","article-title":"The Association of age with Clinical Presentation and Comorbidities of pyoderma Gangrenosum","volume":"154","author":"Ashchyan","year":"2018","journal-title":"JAMA Dermatol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.jaad.2019.09.032","article-title":"Pyoderma gangrenosum in hematologic malignancies: a systematic review","volume":"82","author":"Montagnon","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.2169\/internalmedicine.47.1280","article-title":"Successful treatment of pyoderma gangrenosum associated with myelodysplastic syndrome using high-dose intravenous immunoglobulin","volume":"47","author":"Tamaki","year":"2008","journal-title":"Intern Med"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s10156-003-0254-6","article-title":"Successful treatment of pyoderma gangrenosum that developed in a patient with myelodysplastic syndrome","volume":"9","author":"Yamauchi","year":"2003","journal-title":"J Infect Chemother"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1365-2133.2005.06747.x","article-title":"Thalidomide: dermatological indications, mechanisms of action and side-effects","volume":"153","author":"Wu","year":"2005","journal-title":"Br J Dermatol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/10245330600574177","article-title":"Successful treatment of myelodysplastic syndrome-induced pyoderma gangrenosum","volume":"11","author":"Koca","year":"2006","journal-title":"Neth J Med"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"842","DOI":"10.4065\/75.8.842","article-title":"Recalcitrant pyoderma gangrenosum treated with thalidomide","volume":"75","author":"Federman","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/s0190-9622(98)70513-4","article-title":"Recalcitrant pyoderma gangrenosum: treatment with thalidomide","volume":"38","author":"Hecker","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/s0190-9622(08)80705-0","article-title":"Pyoderma gangrenosum associated with Beh\u00e7et\u2019s disease: treatment with thalidomide","volume":"23","author":"Rustin","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11899-010-0047-9","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"5","author":"Kyle","year":"2010","journal-title":"Curr Hematol Malig Rep"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1111\/iwj.12746","article-title":"Dramatic resolution of disseminated pyoderma gangrenosum associated with monoclonal gammopathy after therapy with bortezomib and dexamethasone","volume":"14","author":"Velasco-Tamariz","year":"2017","journal-title":"Int Wound J"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/iwj.13135","article-title":"Excellent response to bortezomib in a patient with widespread ulcerative pyoderma gangrenosum accompanied by pulmonary involvement and IgA monoclonal gammopathy","volume":"16","author":"Bostan","year":"2019","journal-title":"Int Wound J"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1111\/ijd.15504","article-title":"Pyoderma gangrenosum with plasma cell dyscrasia should be subject for anti-myeloma treatment","volume":"60","author":"Nahi","year":"2021","journal-title":"Int J Dermatol"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00277-021-04524-w","article-title":"Ixazomib as treatment for pyoderma gangrenosum associated with IgA smoldering multiple myeloma","volume":"101","author":"Cespedes","year":"2022","journal-title":"Ann Hematol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"13030\/qt1bk7d8hj","DOI":"10.5070\/D3265048791","article-title":"The dilemma of treating pyoderma gangrenosum associated with monoclonal gammopathy of undetermined significance","volume":"26","author":"Machan","year":"2020","journal-title":"Dermatol Online J"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-023-01931-3","article-title":"Pyoderma Gangrenosum: treatment options","volume":"83","author":"Dissemond","year":"2023","journal-title":"Drugs"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1590\/abd1806-4841.20176373","article-title":"Eosinophilic annular erythema in adults: report of two cases and review of the literature","volume":"92","author":"Heras","year":"2017","journal-title":"An Bras Dermatol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.annder.2021.07.007","article-title":"Treatment of eosinophilic annular erythema: retrospective multicenter study and literature review","volume":"149","author":"Chastagner","year":"2022","journal-title":"Ann Dermatol Venereol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.1468-3083.2005.01052.x","article-title":"Hypereosinophilic dermatitis-like erythema annulare centrifugum in a patient with chronic lymphocytic leukaemia","volume":"19","author":"Miljkovi\u0107","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"13030\/qt1zd6p6z2","DOI":"10.5070\/D3266049329","article-title":"What\u2019s in a name? A new nomenclature has been proposed for eosinophilic dermatosis of hematologic malignancy (EDHM): hematologic-related malignancy-induced eosinophilic dermatosis (he remained)","volume":"26","author":"Cohen","year":"2020","journal-title":"Dermatol Online J"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.jaip.2018.06.002","article-title":"Eosinophil-related disease and the skin","volume":"6","author":"Leiferman","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jaad.2021.07.007","article-title":"Overexpression of helper T cell type 2-related molecules in the skin of patients with eosinophilic dermatosis of hematologic malignancy","volume":"87","author":"Maglie","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood.V26.3.257.257","article-title":"Exaggerated delayed hypersensitivity to mosquito bites in chronic lymphocytic leukemia","volume":"26","author":"Weed","year":"1965","journal-title":"Blood"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1001\/archderm.135.12.1503","article-title":"Insect bite-like reaction in patients with hematologic malignant neoplasms","volume":"135","author":"Barzilai","year":"1999","journal-title":"Arch Dermatol"},{"key":"ref87","first-page":"1378","article-title":"Eosinophilic dermatosis of myeloproliferative disease: characterization of a unique eruption in patients with hematologic disorders","volume":"137","author":"Byrd","year":"2001","journal-title":"Arch Dermatol"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/j.1600-0560.2012.01906.x","article-title":"Eosinophilic dermatosis of hematologic malignancy","volume":"39","author":"Farber","year":"2012","journal-title":"J Cutan Pathol"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1111\/jdv.14805","article-title":"T-cell papulosis associated with B-cell malignancy: a distinctive clinicopathologic entity","volume":"32","author":"Visseaux","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.jaad.2019.08.062","article-title":"Hematologic-related malignancy-induced eosinophilic dermatosis (he Remainded): an eosinophilic dermatosis predominantly associated with chronic lymphocytic leukemia","volume":"82","author":"Cohen","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1097\/IOP.0000000000002004","article-title":"Eosinophilic dermatosis of malignancy involving the eyelid","volume":"37","author":"Ho","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jaad.2018.11.048","article-title":"Eosinophilic dermatosis of hematologic malignancy: a retrospective cohort of 37 patients from an Italian center","volume":"81","author":"Grandi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/ejh.12015","article-title":"Insect-bite-like reaction in patients with chronic lymphocytic leukemia: a study from the Israeli chronic lymphocytic leukemia study group","volume":"89","author":"Bairey","year":"2012","journal-title":"Eur J Haematol"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1002\/ski2.208","article-title":"Folliculocentric lymphocytic hypersensitivity reactions in CLL\/SLL patients: a unique clinicopathologic entity amongst non-specific hypersensitivity reactions","volume":"3","author":"Abbott","year":"2023","journal-title":"Skin Health Dis"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/j.1365-2133.2012.10966.x","article-title":"Insect bite-like reactions in a patient with B-cell chronic lymphocytic leukaemia: fluorescence in situ hybridization analysis revealed neoplastic B cells within the skin infiltrate","volume":"167","author":"Mitteldorf","year":"2012","journal-title":"Br J Dermatol"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/cup.13389","article-title":"Eosinophilic dermatosis of hematologic malignancy: correlation of molecular characteristics of skin lesions and extracutaneous manifestations of hematologic malignancy","volume":"46","author":"Meiss","year":"2019","journal-title":"J Cutan Pathol"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/cup.13932","article-title":"Eosinophilic folliculitis, eosinophilic dermatosis of hematologic malignancy and acneiform follicular mucinosis: two case reports and a review of the literature highlighting the spectrum of histopathology","volume":"48","author":"Bailey","year":"2021","journal-title":"J Cutan Pathol"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"263827","DOI":"10.1155\/2010\/263827","article-title":"Eosinophilic panniculitis and insect bite-like eruption in a patient with chronic lymphocytic leukaemia: a spectrum of the same entity","volume":"2010","author":"Rodr\u00edguez-Lojo","year":"2010","journal-title":"Dermatol Res Pract"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.jaci.2022.02.007","article-title":"Urticarial vasculitis: clinical and laboratory findings with a particular emphasis on differential diagnosis","volume":"149","author":"Marzano","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5826\/dpc.0703a02","article-title":"Eosinophilic dermatosis of hematologic malignancy mimicking varicella zoster infection: report in a woman with chronic lymphocytic leukemia and review of the literature","volume":"7","author":"Bari","year":"2017","journal-title":"Dermatol Pract Concept"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"e501","DOI":"10.1111\/jdv.17232","article-title":"Dupilumab for the treatment of recalcitrant eosinophilic dermatosis of haematologic malignancy","volume":"35","author":"Maglie","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.1111\/jdv.17748","article-title":"Efficacy of dupilumab in eosinophilic dermatosis of haematologic malignancy (EDHM) needs to be confirmed","volume":"36","author":"Sibaud","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jdcr.2019.07.026","article-title":"Eosinophilic dermatosis of hematologic malignancy responding to dupilumab in a patient with chronic lymphocytic leukemia","volume":"5","author":"Jin","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref104","doi-asserted-by":"publisher","first-page":"e13725","DOI":"10.1111\/dth.13725","article-title":"Targeted inhibition of IL-4\/13 with dupilumab is an effective treatment for eosinophilic dermatosis of hematologic malignancy","volume":"33","author":"Goyal","year":"2020","journal-title":"Dermatol Ther"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/ddg.13132","article-title":"Wells syndrome","volume":"14","author":"Weins","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1001\/archderm.142.9.1157","article-title":"Wells syndrome in adults and children: a report of 19 cases","volume":"142","author":"Caputo","year":"2006","journal-title":"Arch Dermatol"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3315\/jdcr.2013.1157","article-title":"Wells syndrome (eosinophilic cellulitis): proposed diagnostic criteria and a literature review of the drug-induced variant","volume":"7","author":"Heelan","year":"2013","journal-title":"J Dermatol Case Rep"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/DAD.0000000000000279","article-title":"Idiopathic Hypereosinophilic syndrome with cutaneous manifestations and flame figures: a Spectrum of eosinophilic dermatoses whose features overlap with Wells\u2019 syndrome","volume":"37","author":"Smith","year":"2015","journal-title":"Am J Dermatopathol"},{"key":"ref109","first-page":"1683","article-title":"Flame figures associated with eosinophilic dermatosis of hematologic malignancy: is it possible to distinguish the condition from eosinophilic cellulitis in patients with hematoproliferative disease?","volume":"6","author":"Qiao","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1365-2133.2006.07345.x","article-title":"Insect-bite-like Wells\u2019 syndrome in association with mantle-zone lymphoma","volume":"155","author":"Zeeli","year":"2006","journal-title":"Br J Dermatol"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"10997","DOI":"10.12998\/wjcc.v10.i30.10997","article-title":"Wells\u2019 syndrome possibly caused by hematologic malignancy, influenza vaccination or ibrutinib: a case report","volume":"10","author":"\u0160ajn","year":"2022","journal-title":"World J Clin Cases"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"e274","DOI":"10.1111\/j.1365-2230.2008.03192.x","article-title":"Impetiginized Wells\u2019 syndrome in a patient with chronic lymphocytic leukaemia","volume":"34","author":"Gambichler","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1684\/ejd.2011.1296","article-title":"Eosinophilic cellulitis (Wells\u2019 syndrome) and an insect bite-like reaction in a patient with non-Hodgkin B cell lymphoma","volume":"21","author":"Misago","year":"2011","journal-title":"Eur J Dermatol"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"5579","DOI":"10.1182\/blood.V128.22.5579.5579","article-title":"Steroid dependent recalcitrant Well\u2019s syndrome in a patient with chronic lymphocytic leukemia (CLL) responding to hydroxychloroquine (HCQS)","volume":"128","author":"Prabhsimranjot","year":"2016","journal-title":"Blood"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/jdv.12652","article-title":"Chronic relapsing eosinophilic cellulitis associated, although independent in severity, with chronic lymphocytic leukemia","volume":"30","author":"Shin","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/ijd.12257","article-title":"Pruritic nodules and plaques on the arms with blisters in a patient with chronic lymphocytic leukemia","volume":"53","author":"Lorente-Lavirgen","year":"2014","journal-title":"Int J Dermatol"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/s0190-9622(03)00466-3","article-title":"Eosinophilic cellulitis as a cutaneous manifestation of idiopathic hypereosinophilic syndrome","volume":"49","author":"Fujii","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1046\/j.1365-2133.1997.19972078.x","article-title":"Wells\u2019 syndrome associated with idiopathic hypereosinophilic syndrome","volume":"137","author":"Bogenrieder","year":"1997","journal-title":"Br J Dermatol"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jdcr.2022.01.022","article-title":"Idiopathic hypereosinophilic syndrome with eosinophilic cellulitis-like cutaneous involvement treated with mepolizumab and dapsone","volume":"22","author":"Lachance","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref120","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/j.1365-2133.2006.07490.x","article-title":"Eosinophilic cellulitis as a presenting feature of chronic eosinophilic leukaemia, secondary to a deletion on chromosome 4q12 creating the FIP1L1-PDGFRA fusion gene","volume":"155","author":"Davis","year":"2006","journal-title":"Br J Dermatol"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1001\/archderm.140.5.584","article-title":"Unexplained hypereosinophilia and the need for cytogenetic and molecular genetic analyses","volume":"140","author":"Smith","year":"2004","journal-title":"Arch Dermatol"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/jdv.13706","article-title":"Treatment of eosinophilic cellulitis (Wells syndrome) - a systematic review","volume":"30","author":"R\u00e4\u00dfler","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1111\/ddg.14598","article-title":"Dupilumab in eosinophilic cellulitis (Wells\u2019 syndrome) - case report of a potential new treatment option","volume":"19","author":"Traidl","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"e454","DOI":"10.1111\/ijd.16501","article-title":"Wells syndrome successfully treated with dupilumab","volume":"62","author":"Kirven","year":"2023","journal-title":"Int J Dermatol"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/ddg.14151","article-title":"Effective treatment with mepolizumab in a patient with refractory Wells syndrome","volume":"18","author":"Terhorst-Molawi","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.jdcr.2018.02.011","article-title":"Eosinophilic cellulitis (Wells syndrome) successfully treated with mepolizumab","volume":"4","author":"Herout","year":"2018","journal-title":"JAAD Case Rep"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"adv00332","DOI":"10.2340\/00015555-3697","article-title":"Treatment of widespread eosinophilic cellulitis (Wells\u2019 syndrome) with Benralizumab","volume":"100","author":"Blomberg","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1001\/jamadermatol.2023.1651","article-title":"Hyperactivation of the JAK2\/STAT5 signaling pathway and evaluation of Baricitinib treatment among patients with eosinophilic cellulitis","volume":"159","author":"Morot","year":"2023","journal-title":"JAMA Dermatol"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/ajh.26966","article-title":"The international consensus classification of eosinophilic disorders and systemic mastocytosis","volume":"98","author":"Wang","year":"2023","journal-title":"Am J Hematol"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.jaip.2022.03.034","article-title":"Clinical profile and treatment in Hypereosinophilic syndrome variants: a pragmatic review","volume":"10","author":"Requena","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/ddg.14083","article-title":"Recurrent hemorrhagic blisters: an atypical presentation of lymphocytic hypereosinophilic syndrome with cutaneous manifestations","volume":"18","author":"Rodr\u00edguez-Lomba","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/bjd.21782","article-title":"Cutaneous manifestations of lymphoid-variant hypereosinophilic syndrome","volume":"187","author":"Laurent","year":"2022","journal-title":"Br J Dermatol"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/ajh.25945","article-title":"Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: data from 151 patients","volume":"95","author":"Rohmer","year":"2020","journal-title":"Am J Hematol"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/MD.0b013e3182a71eba","article-title":"The Spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new insights based on a survey of 44 Cases","volume":"92","author":"Legrand","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1001\/jama.1982.03320320054032","article-title":"Recurrent incapacitating mucosal ulcerations. A prodrome of the hypereosinophilic syndrome","volume":"247","author":"Leiferman","year":"1982","journal-title":"JAMA"},{"key":"ref136","first-page":"207","article-title":"Mucosal ulcerations revealing primitive hypereosinophilic syndrome","volume":"13","author":"Barouky","year":"2003","journal-title":"Eur J Dermatol"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jaci.2003.10.051","article-title":"Hypereosinophilic syndrome: case presentation and update","volume":"113","author":"Leiferman","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/1346-8138.14888","article-title":"Pemphigus-like hypereosinophilic syndrome with FIP1L1-PDGFRA fusion gene: a challenging and uncommon clinical presentation","volume":"46","author":"Curto-Barredo","year":"2019","journal-title":"J Dermatol"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"bcr2015213266","DOI":"10.1136\/bcr-2015-213266","article-title":"Oral mucosal manifestations of chronic eosinophilic leukaemia with FIP1L1-PDGFR\u03b1","volume":"2016","author":"Tsuda","year":"2016","journal-title":"BMJ Case Rep"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.annder.2012.05.008","article-title":"Syndrome hyper\u00e9osinophilique d\u2019origine my\u00e9loprolif\u00e9rative r\u00e9v\u00e9l\u00e9 par des ulc\u00e9rations muqueuses bipolaires [Myeloproliferative hypereosinophilic syndrome revealed by bipolar mucosal ulcerations]","volume":"139","author":"Isvy-Joubert","year":"2012","journal-title":"Ann Dermatol Venereol"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"648","DOI":"10.7326\/0003-4819-121-9-199411010-00003","article-title":"Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome","volume":"121","author":"Butterfield","year":"1994","journal-title":"Ann Intern Med"},{"key":"ref142","first-page":"248","article-title":"Ulc\u00e9rations muqueuses isol\u00e9es r\u00e9v\u00e9latrices d\u2019un syndrome hyper\u00e9osinophilique idiopathique [Isolated mucosal ulcers disclosing idiopathic hypereosinophilic syndrome]","volume":"124","author":"Billon","year":"1997","journal-title":"Ann Dermatol Venereol"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/j.oooo.2013.03.017","article-title":"Hypereosinophilic syndrome - lymphocytic variant transforming into peripheral T-cell lymphoma with severe oral manifestations","volume":"116","author":"d\u2019Elb\u00e9e","year":"2013","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1111\/1346-8138.16836","article-title":"Lymphomatoid papulosis associated with myeloid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement: successful imatinib treatment in two cases","volume":"50","author":"Bellani","year":"2023","journal-title":"J Dermatol"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/ced\/llac112","article-title":"Detection of FIP1L1-PDGFRA fusion gene-positive cells in the skin lesion of a patient with hypereosinophilic syndrome","volume":"48","author":"Kitayama","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1182\/blood-2007-11-126268","article-title":"FIP1L1\/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia\/hypereosinophilic syndrome","volume":"112","author":"Yamada","year":"2008","journal-title":"Blood"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000351807","article-title":"Clonal mast cell proliferation in pruriginous skin in hypereosinophilic syndrome","volume":"227","author":"Wiednig","year":"2013","journal-title":"Dermatology"},{"key":"ref148","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1182\/blood-2003-07-2274","article-title":"Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities?","volume":"102","author":"Tefferi","year":"2003","journal-title":"Blood"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"bcr2018227137","DOI":"10.1136\/bcr-2018-227137","article-title":"Idiopathic hypereosinophilic syndrome with cutaneous involvement: a comparative review of 32 cases","volume":"11","author":"Inayat","year":"2018","journal-title":"BMJ Case Rep"},{"key":"ref150","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1590\/abd1806-4841.20187419","article-title":"Case for diagnosis. Erythroderma as manifestation of hypereosinophilic syndrome","volume":"93","author":"Merlotto","year":"2018","journal-title":"An Bras Dermatol"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jaip.2019.12.011","article-title":"Idiopathic eosinophilic vasculitis: another side of hypereosinophilic syndrome? A comprehensive analysis of 117 cases in asthma-free patients","volume":"8","author":"Lef\u00e8vre","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref152","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1046\/j.1365-2133.2001.04207.x","article-title":"Digital necrosis in a patient with hypereosinophilic syndrome in the absence of cutaneous eosinophilic vasculitis","volume":"144","author":"Oppliger","year":"2001","journal-title":"Br J Dermatol"},{"key":"ref153","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1046\/j.1365-2133.2003.05309.x","article-title":"Idiopathic hypereosinophilic syndrome associated with cutaneous infarction and deep venous thrombosis","volume":"148","author":"Narayan","year":"2003","journal-title":"Br J Dermatol"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1001\/archderm.143.6.812","article-title":"Hypereosinophilic syndrome with peripheral circulatory insufficiency and cutaneous microthrombi","volume":"143","author":"Hamada","year":"2007","journal-title":"Arch Dermatol"},{"key":"ref155","doi-asserted-by":"publisher","first-page":"e15392","DOI":"10.1097\/MD.0000000000015392","article-title":"Hypereosinophilic vasculitis: a case report","volume":"98","author":"Alzayer","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"ref156","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1111\/j.1365-2230.2008.03008.x","article-title":"Hypereosinophilic syndrome with various skin lesions and juvenile temporal arteritis","volume":"34","author":"Ito","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"ref157","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1365-2133.2000.03726.x","article-title":"Hypereosinophilic syndrome presenting as cutaneous necrotizing eosinophilic vasculitis and Raynaud\u2019s phenomenon complicated by digital gangrene","volume":"143","author":"Jang","year":"2000","journal-title":"Br J Dermatol"},{"key":"ref158","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1016\/j.jaip.2023.05.010","article-title":"Digital ischemia as a presenting feature of Hypereosinophilic syndrome-associated Vasculitis","volume":"11","author":"Serrano-Santiago","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref159","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1111\/1346-8138.16279","article-title":"Eosinophilic vasculitis as a manifestation of idiopathic hypereosinophilic syndrome","volume":"49","author":"Kanno","year":"2022","journal-title":"J Dermatol"},{"key":"ref160","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2169\/internalmedicine.3707-19","article-title":"Development of eosinophilic temporal arteritis and digital ischemia in a patient with hypereosinophilic syndrome","volume":"59","author":"Ishii","year":"2020","journal-title":"Intern Med"},{"key":"ref161","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1067\/mjd.2002.107233","article-title":"Necrotic cutaneous lesions induced by hypereosinophilic syndrome secondary to a T-cell lymphoma","volume":"46","author":"Aractingi","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"ref162","doi-asserted-by":"publisher","first-page":"264","DOI":"10.4103\/ijd.IJD_432_17","article-title":"Interstitial granulomatous dermatitis due to a rare myeloproliferative neoplasia","volume":"63","author":"Cases-Merida","year":"2018","journal-title":"Indian J Dermatol"},{"key":"ref163","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/cup.14410","article-title":"Clinical and histopathological features of hypereosinophilic syndrome with cutaneous involvement: the Mayo Clinic experience","volume":"50","author":"Zayas","year":"2023","journal-title":"J Cutan Pathol"},{"key":"ref164","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1080\/10428194.2016.1190965","article-title":"Complete remission of disseminated granulomatous dermatitis related to chronic eosinophilic leukemia following allogeneic stem cell transplantation","volume":"58","author":"Beauverd","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"ref165","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/bjh.18569","article-title":"T(9,12)(q22;p13) ETV6::SYK: a new recurrent cytogenetic aberration and tyrosine kinase gene fusion in myeloid or lymphoid neoplasms associated with eosinophilia","volume":"200","author":"Lierman","year":"2023","journal-title":"Br J Haematol"},{"key":"ref166","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jdcr.2018.05.005","article-title":"Thalidomide as an effective treatment for adult multiple xanthogranuloma","volume":"4","author":"Debois","year":"2018","journal-title":"JAAD Case Rep."},{"key":"ref167","doi-asserted-by":"publisher","first-page":"101014","DOI":"10.1016\/j.blre.2022.101014","article-title":"Biologic therapies for hypereosinophilic disorders: from tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?","volume":"58","author":"Iurlo","year":"2023","journal-title":"Blood Rev"},{"key":"ref168","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1111\/bjh.16332","article-title":"Pegylated interferon alpha 2a is an effective and well-tolerated treatment option for lymphocyte-variant hypereosinophilic syndrome","volume":"188","author":"Choi","year":"2020","journal-title":"Br J Haematol"},{"key":"ref169","doi-asserted-by":"publisher","first-page":"1035250","DOI":"10.3389\/fmed.2023.1035250","article-title":"Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome","volume":"10","author":"Roufosse","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"ref170","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative Hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N Engl J Med"},{"key":"ref171","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1007\/s10875-020-00946-9","article-title":"Benralizumab in severe and refractory PDGFRA-negative Hypereosinophilic syndrome","volume":"41","author":"Alen Coutinho","year":"2021","journal-title":"J Clin Immunol"},{"key":"ref172","doi-asserted-by":"publisher","first-page":"e00665","DOI":"10.1002\/rcr2.665","article-title":"Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab","volume":"8","author":"Fujii","year":"2020","journal-title":"Respirol Case Rep"},{"key":"ref173","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00011-023-01715-1","article-title":"A case of complete recovery in a hypereosinophilic dermatitis patient with dupilumab","volume":"72","author":"Jiang","year":"2023","journal-title":"Inflamm Res"},{"key":"ref174","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/ajd.14086","article-title":"Hypereosinophilic syndrome with cutaneous manifestations successfully treated with Dupilumab as a sole agent: a case report","volume":"64","author":"Scully","year":"2023","journal-title":"Australas J Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1324258\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T05:22:13Z","timestamp":1704432133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1324258\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":174,"alternative-id":["10.3389\/fmed.2023.1324258"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1324258","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]},"article-number":"1324258"}}